A model of metformin mitochondrial metabolism in metachromatic leukodystrophy: first description of human Schwann cells transfected with CRISPR-Cas9

Nayibe Tatiana Sanchez-Álvarez1,2,3, Paula Katherine Bautista-Niño3, Juanita Trejos-Suárez1 and Norma Cecilia Serrano-Díaz3

1 Faculty of Medical and Health Sciences, Masita Institute for Biomedical Research, Universidad de Santander, Bucaramanga, Colombia
2 Faculty of Health, PhD in Biomedical Sciences, Universidad del Valle, Cali, Colombia
3 Research Center Floridablanca, Colombian Cardiovascular Foundation, FL, Colombia

Received: 13 December 2021
Accepted: 8 June 2022

Subject Area: neuroscience/cellular biology/molecular biology/genetics

Keywords: metachromatic leukodystrophy (MLD), metabolic activity, metformin, neurological lysosomal storage disease, sulfatide therapy

1. Introduction

Metachromatic leukodystrophy (MLD) is a lysosomal storage disease classified as an inborn error of metabolism that is inherited in an autosomal recessive manner. It is characterized by progressive demyelination of the central nervous system (CNS) and peripheral nervous system (PNS), causing severe neurological symptoms [1–3]. MLD is caused by different mutations in the arylsulfatase A gene, hereinafter referred to as ARSA, located on chromosome 22q13.33, comprising eight exons and encoding a 509 amino acid precursor protein [4,5].

To date, nearly 200 genetic mutations have been identified [6]. Most of them are nonsense mutations, thus leading to deficient expression or structural damage of ARSA [7]. ARSA is a lysosomal acid hydrolase that catalyses the first step in the degradation of cerebroside 3-sulfate, a sulfatide mainly found in CNS white matter and PNS [8,9].
2. Material and methods

2.1. Cell culture

Human Schwann cells (HSCs) isolated from human spinal nerve (Sciencell Research Laboratories [15]) were selected for this study. Cells were thawed to assess their viability using 0.4% trypan blue dye in a Neubauer chamber and then cultured in Schwann cell medium (MCS, Sciencell Research Laboratories) in an environment with 5% CO₂ concentration. Cell expansion was carried out by limiting dilution, incubated in medium, Lipofectamine Cas9 Plus Reagent, GeneArt Platinum Cas9 nuclease and Lipofectamine CRISPRMAX were added according to manufacturer's instructions. sgRNA (GACCCUGGGCCGAAGU) (Synthego) is a 20-nucleotide gene sequence that is homologous to exon 2 of the ARSA gene directing Cas9 nuclease activity. sgRNA sequence was used to align two or more sequences (https://blast.ncbi.nlm.nih.gov/Blast.cgi) [17] to Homo sapiens chromosome 22 (NC_000022.11) [2] for analysing and positioning guide RNA sequences and/or primers.

Cells cultured in the 24-well plate were trypsinized and 50 µl of the sgRNA and Opti-MEM mix in reduced serum medium, Lipofectamine Cas9 Plus Reagent, GeneArt Platinum Cas9 nuclease and Lipofectamine CRISPRMAX were added to the wells. Additionally, Lipofectamine transfection reagent was added to the transfection reagent according to the manufacturer’s instructions [18]. Cells were incubated at 37°C in an atmosphere of 5% CO₂ for 3 days. After incubation, cloning cell expansion was carried out by limiting dilution, incubated at 37°C in an atmosphere of 5% CO₂ until 80% confluence and transferred to a 60 mm² Petri dish for subsequent assays.

2.2. Cell transfection

Cultured HSC density increased between 30% and 70% 24 h after seeding on assays, which corresponds to approximately 2 × 10⁴ cells per well on 24-well plates (Corning, Life Sciences). The CRISPR-Cas9 assay was performed with 500 µl of MCS. In addition, ribonucleoprotein complex assembly was performed at a ratio of 1.3:1 of custom single guide RNA containing a targeting sequence (sgRNA). GeneArt Platinum Cas9 nuclease (Life Technologies) and Lipofectamine CRISPRMAX Cas9 Transfection Reagent (Invitrogen) were used according to the manufacturer's instructions. sgRNA (GACCCUGGGCCGAAGU) (Synthego) is a 20-nucleotide gene sequence that is homologous to exon 2 of the ARSA gene directing Cas9 nuclease activity. sgRNA sequence was used to align two or more sequences (https://blast.ncbi.nlm.nih.gov/Blast.cgi) [17] to Homo sapiens chromosome 22 (NC_000022.11) [2] for analysing and positioning guide RNA sequences and/or primers.

The CRISPR-Cas9 assay was performed with 500 µl of MCS. In addition, ribonucleoprotein complex assembly was performed at a ratio of 1.3:1 of custom single guide RNA containing a targeting sequence (sgRNA). GeneArt Platinum Cas9 nuclease (Life Technologies) and Lipofectamine CRISPRMAX Cas9 Transfection Reagent (Invitrogen) were used according to the manufacturer’s instructions. sgRNA (GACCCUGGGCCGAAGU) (Synthego) is a 20-nucleotide gene sequence that is homologous to exon 2 of the ARSA gene directing Cas9 nuclease activity. sgRNA sequence was used to align two or more sequences (https://blast.ncbi.nlm.nih.gov/Blast.cgi) [17] to Homo sapiens chromosome 22 (NC_000022.11) [2] for analysing and positioning guide RNA sequences and/or primers.

Cells cultured in the 24-well plate were trypsinized and 50 µl of the sgRNA and Opti-MEM mix in reduced serum medium, Lipofectamine Cas9 Plus Reagent, GeneArt Platinum Cas9 nuclease and Lipofectamine CRISPRMAX were added to the wells. Additionally, Lipofectamine transfection reagent was added to the transfection reagent according to the manufacturer’s instructions [18]. Cells were incubated at 37°C in an atmosphere of 5% CO₂ for 3 days. After incubation, cloning cell expansion was carried out by limiting dilution, incubated at 37°C in an atmosphere of 5% CO₂ until 80% confluence and transferred to a 60 mm² Petri dish for subsequent assays.

2.3. Real-time reverse transcriptase-polymerase chain reaction

ARSA expression in Schwann cells was quantified before and after transfection with CRISPR-Cas9. In addition, RNA extraction was performed using TRIzol reagent (Ambion). RNA concentration and quality were measured spectrophotometrically using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific) at a A260/A280 ratio of 1.75. In addition, real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) assays were performed using 2X Luna Universal Probe One-Step RT-qPCR (New England Biolabs), 0.4 µM pre-designed forward/reverse TaqMan gene expression assay primers (Life Technologies) + FAM-labelled TaqMan probe fluorophore, 20X Luna WarmStart RT enzyme mix and sample RNA with the concentration of 100 ng µl⁻¹ in a final volume of 20 µl. Thermal cycling was performed at 55°C for 20 min (reverse transcription), followed by 45 cycles of 95°C for 5 min, 95°C for 15 s, 60°C for 45 s and a final extension at 60°C for 5 min for a 69 bp amplicon. Results were analysed using Bio-Rad CFX Manager version 3.1.1517.0823 [19].

To determine the number of copies expressed in the ARSA gene of transfected cells compared to non-transfected cells, the relative quantification method was analysed, using endogenous control genes glyceraldehyde-3-phosphate dehydrogenase with the formula:

\[
\Delta Ct = Ct\text{ Transfected cells} - Ct\text{ Untransfected cells} \\
\Delta Ct = Ct\text{ ARSA gene} - Ct\text{ GAPDH gene} \\
\Delta Ct = Ct\text{ ARSA gene} - Ct\text{ GAPDH gene} \\
\Delta GDCt = Ct\text{ Transfected cells} - Ct\text{ Untransfected cells} \\
\Delta \Delta ct = Ct\text{ ARSA gene} - Ct\text{ GAPDH gene} \\
\Delta \Delta ct = Ct\text{ ARSA gene} - Ct\text{ GAPDH gene}
\]

2.4. Sequencing and bioinformatics analysis

Before sequencing exon 2 of the ARSA gene for the analysis of mutation in transfected cells, conventional PCR amplification was performed in a final volume of 50 µl with 2X Master
Mix Go Taq Green (Promega), 10 nM of primer forward 5’CCTACCTGGCTGGAGTA3’, primer reverse 5’GGTTCCCG CGAGCGGGCGC’ and 100 ng of DNA. Thermal cycling was performed at 94°C for 5 min, followed by 35 cycles of 94°C for 30 s, 60.5°C for 40 s, 72°C for 30 s and 72°C for 5 min. Electrophoresis was performed on a 1.0% agarose gel at 80 volts for 45 min to obtain a 256-base pair (bp) band. PCR products were sequenced by capillary electrophoresis (Macrogen Inc.). Once the sequence was obtained, the assembly was performed using SeqMan Ultra-LaserGene version 17 (DNASTAR) [20], which is homologous with exon 2 of the ARSA gene (NG_009260.2) [21]. Based on observed differences, a high-resolution three-dimensional theoretical structural model of the protein was developed using the Swiss Model Server Structure Evaluation Tool [22] by using the human aroylsulfatase protein sequence as template A (PDB ID: 1AUk) [23].

2.5. Cell viability and cytotoxicity

Cell viability and proliferation were assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo (MTT) bromide method (Alpha Aesar). Cell cytotoxicity enabled determination of sulfatide and metformin concentrations for subsequent testing. In each assay, MCS was served as an untreated control to normalize treatment results.

HSCs were seeded in 96-well plates at a density of 2 x 10^4 cells per well tested and incubated at 37°C in a 5% CO2 atmosphere for 24 h. The cells were exposed to 10, 25, 50 and 100 µM sulfatide (Matreya) in the same plate and exposed to 10, 25, 50, 100, 300 and 1000 µM metformin (1,1 dimethylbigunide hydrochloride, 97%, Acros Organics). After 24 h incubation, the medium was replaced with MTT dissolved in MCS at a concentration of 1 mg ml⁻¹ for 1 h in a 5% CO2 atmosphere at 37°C, after which MTT was removed from each well and replaced with 100 µl of ACS grade dimethyl sulfoxide (Amresco). Colour intensity was measured spectrophotometrically by a Varioskan Flash microplate reader (Thermo Fisher Scientific) at a wavelength of 570 nm.

For analyses, mean, standard deviation and level of cytotoxicity were determined in accordance with ISO 10993-5:2009, following the classification of cytotoxicity scores according to the percentage of viable cells: 71–100% for non-cytotoxic and less than 70% for potentially cytotoxic [24].

2.6. Evaluation of cell death

Non-transfected and transfected cells were cultured in 96-well plates at a density of 3 x 10^4 cells per well at 37°C for 2 h in a 5% CO2 atmosphere for subsequent treatment with different concentrations of sulfatide and metformin dissolved in the culture medium. After treatment, they were incubated at 37°C in a 5% CO2 atmosphere for 24 h. On the day of the assay, cell death was determined by incubating cells with 0.05 µM SYTOX Green nucleic acid stain (Invitrogen) dissolved in MCS (MCS-SYTOX). One hundred microlitres of MCS-SYTOX was added to each well, followed by an incubation for 15 min during which the Varioskan Flash microplate reader (Thermo Fisher Scientific) was used to determine fluorescence.

To determine the number of dead cells and average fluorescence of wells in triplicate, the ratio between control well fluorescence and fluorescence of wells containing lysed cells in the presence of 0.1% Triton X-100 (Amresco) was used as a positive and negative control with MCS. Increased fluorescence is associated with increased cell death.

2.7. Apoptosis

Apoptosis was assessed using caspases 3/7 and annexin V assays to differentiate apoptotic and necrotic processes. HSCs were seeded until reaching 70% confluence. Caspase-3 and -7 activities were determined using the CellEvent Caspase-3/7 Green Flow Cytometry Assay Kit (Life Technologies).

In addition, HSCs were treated with 100 µM sulfatide and 500 µM metformin in culture and incubated for 24 h at 37°C with a CO2 concentration of 5%. Four micromoles of doxorubicin was used as a positive control (Ebewe). Cytometry tubes each containing 1 ml of cell suspension in phosphate-buffered saline were treated according to the manufacturer’s instructions [25]. Finally, samples were analysed using a 488 nm excitation filter, 530/30 (green) emission filter for CellEvent reagent and 690/50 (red) filter for SYTOX ADVanced. Cell viability was measured with a FACScan III flow cytometer (BD Biosciences). A minimum of 2000 events were recorded.

Phosphatidylserine translocation from the inner to the outer leaflet of the cellular membrane as a differentiator of apoptosis and mitochondrial membrane potential in live cells was evaluated using the MitoTracker Red and Alexa Fluor 488 Annexin V Kit (Invitrogen) by flow cytometry using the FACScan III Kit (BD Biosciences) to acquire 2000 events according to the manufacturer’s instructions [26]. This assay is based on the detection of phosphatidylserine translocation and changes in mitochondrial membrane potential.

Apoptosis was induced in HSCs after treatment with 10, 25, 50 and 100 µM sulfatide, 500 µM metformin, 100 µM sulfatide and 500 µM metformin. Negative control results were prepared by incubating the cells in the absence of any inducing agent. These cells were incubated using 4 µM doxorubicin as a positive control for necrosis (Ebewe).

In addition, apoptotic cells show a strong green fluorescence with decreased red fluorescence in comparison to very little green fluorescence and bright red fluorescence in living cells. These populations can be easily distinguished using a flow cytometer to measure fluorescence emission spectra at 530 and 585 nm.

2.8. Mitochondrial bioenergetics

As recommended in the Mito Stress Test Kit protocol (Agilent Technologies) [27], the standardization of the number of cells and the concentration of carboxyfluorescein-d trifluoromethoxyphenylhydrazone (FCCP, ChemScene) were carried out in response to this uncoupler to ensure optimal and reproducible culture conditions for comparability between data and scientific results collected from HSC. Therefore, the total cell population was 50,000 cells.

Non-transfected and transfected HSCs were cultured in Seahorse 24-well plates (Agilent Technologies) at a density of 5 x 10^4 cells in 100 µl of MCS and treated with 150 µl of 10, 25, 50 and 100 µM sulfatide and 500 µM metformin for 24 h at 37°C with 5% CO2 for 2 h. The mitochondrial bioenergetic function was determined using the XF Cell Mito Stress Test kit to measure mitochondrial metabolism (Agilent Technologies) using extracellular flux analysis on a Seahorse XFe24 Analyzer (Agilent Technologies) following the manufacturer’s instructions [27].
At the end of each assay run, the Bradford assay was used to determine protein concentration. To normalize the assay, proteins were read at a wavelength of 590 nm using a Thermo Scientific Varioskan Flash plate reader (Thermo Fisher Scientific).

One hour before starting the experiment, HSCs were washed and replaced with DMEM (Caisson Labs) without buffer, supplemented with 1 mM pyruvate, 10 mM glutamine and 5.5 mM glucose, and the medium was adjusted to pH 7.4. After establishing the baseline cellular oxygen consumption rate and extracellular acidification rate (ECAR), metabolic changes are measured by adding inhibitors, 1.5 µM oligomycin (ChemScene) and 1 µM FCCP and antimycin A/rotenone (ChemScene).

2.9. Mitochondrial reactive oxygen species

Mitochondrial reactive oxygen species (ROS) levels were measured using a MitoSOX Red fluorescent probe (Invitrogen) following the manufacturer’s instructions [28]. Fluorescence intensity was measured using an Eclipse Ti-S inverted microscope (Nikon) at a 510/580 nm for emission/excitation.

2.10. Statistical analysis

Statistical analyses were performed using GraphPad Prism 8 (Graphpad Software) [29]. All data are presented as the mean ± s.e.m. Statistical differences between both groups were analysed using t-tests for unpaired data. When evaluating both groups, these were analysed by one-way analysis of variance using the Bonferroni test. p-values of *p < 0.05, **p < 0.01 and ***p < 0.001 were considered statistically significant.

3. Results

3.1. Cell transfection

In the analysis of results, cell transfection, RT-qPCR, and bioinformatics analysis and sequencing were discussed jointly, showing the characteristics of these analyses in both transfected and non-transfected cells.

First, cell transfection shows that transfected cells were obtained using the CRISPR-Cas9 system, modified for the ARSA gene, and all tests were based on the original ARSA gene sequencing (Gene ID: 410) [30] to ensure that both cell populations were functional (transfected and non-transfected cells).

Such genetic modification was confirmed by the gene variant reported in the Leiden Open Variation Database (LOVD3 whole-genome sequencing dataset) [24,31], which is homologous to the variant defined and recorded on 16 February 2016, with a single-nucleotide polymorphism (SNPs74588435 recorded at position chr22: 50 627 213–50 627 219 [32]. In this case, the allele was a deletion of the guanine base (delG)-NM_000487.6, causing a frameshift mutation [31] that is probably and pathologically associated with infantile MLD. The generation of mutations in Schwann cells allowed in vitro experimental simulation of the dynamic of Schwann cells in patients with MLD.

Second, real-time reverse transcriptase polymerase chain reaction (RT-qPCR) allowed us to verify the expression of the ARSA gene, whose result was 42.78 ± 0.07 s.d. in transfected cells versus 33.36 ± 0.03 s.d. in non-transfected cells with ARSA expression, which decreased by 183.5% in transfected cells compared to non-transfected cells.

Finally, sequencing and bioinformatics analysis where the presence of ARSA was verified in both transfected and non-transfected cells using conventional PCR amplification and sequencing analysis showed 99% identity with the sequence of exon 2 of the ARSA gene (ID NG_009260.2), in which c.418del, a mutation previously reported as NM_000487.6:c.418del (dbSNP:rs745884435) [19]: H140 [CAT] > I140 [AT]. In molecular modelling of the three-dimensional structure of the protein used to compare structural similarities, a difference in protein folding was evidenced whenever an amino acid change occurred at this position (figure 1).

3.2. Cell viability and cytotoxicity

Cell viability was 100% in non-transfected Schwann cells exposed to different concentrations of 10–100 µM sulfatide and 10–1000 µM metformin for 24 h.

It should be noted that, to evaluate the effect of sulfatide accumulation in transfected and non-transfected Schwann cells, it is essential to determine cell cytotoxicity using an MTT assay, as well as sulfatide and metformin treatments used in other assays proposed for this research. According to the results obtained from the exposure of both cells populations to sulfatides and metformin, it was possible to select concentrations that did not produce cell death.

Figure 2 shows the percentage of cell viability in non-transfected Schwann cells exposed to concentrations of 10 to 100 of sulfatides and 10 to 100 µM of metformin for 24 h.
In this assay, the treatment using selected sulfatides and metformin concentrations are observed to not cause cell death.

3.3. Evaluation of cell death

As transfected and non-transfected Schwann cells were treated using concentrations of 10, 25, 50 and 100 µM of sulfatides, cell death increased, although a statistically significant difference of \( p = 0.0124 \) was found exclusively in the 100 µM concentration between transfected and non-transfected Schwann cells (figure 3). Therefore, this concentration was chosen to identify whether metformin could mitigate cell death by sulfatide accumulation in transfected Schwann cells. In addition, statistically significant differences of \( p = 0.0124 \) were found in transfected cells over the three treatments when using 100 µM of sulfatides (\( p = 0.0241 \)), combined treatment with sulfatide and metformin and 500 µM of metformin (\( p = 0.0042 \)), (figure 4).

3.4. Apoptosis

One hundred micromoles of sulfatide did not activate caspase 3/7 in non-transfected Schwann cells, which is used as a measure of apoptotic or necrotic cell death. Similarly, 100 µM of sulfatide induced an increase in necrotic cell death in transfected Schwann cells. In addition, simultaneous treatment with sulfatide and metformin enhanced apoptosis and necrosis in these cells.

The analysis of cell apoptosis by flow cytometry showed that both transfected and non-transfected Schwann cells were...
exposed to 100 µM sulfatide or 100 µM sulfatide + 500 µM metformin but only 500 µM metformin showed a statistically significant effect difference between apoptotic and live cells (figure 5).

3.5. Mitochondrial bioenergetics

The ideal FCCP concentration was 0.5 µM so that maximal oxygen consumption and basal respiration would not be less than 20 pmol min µg⁻¹. Using the XF Cell Mito Stress Test Kit, non-transfected Schwann cells exposed to sulfatides at concentrations of 10, 25 and 50 µM were able to show metabolic response as evidenced by increased maximal respiration. However, this response did not occur when cells were exposed at a concentration of 100 µM as their basal oxygen consumption, maximal respiration and reserve capacity decreased (figure 6).

When comparing the results with those of transfected Schwann cells, these cells showed an increase in maximal respiration without sulfatide exposure. However, as sulfatide concentration increased, respiration and basal respiration were affected (figure 6).

Similarly, transfected Schwann cells showed an increase in ECAR rates compared to non-transfected Schwann cells (figure 7).

Differences were observed in energy phenotype maps between the two groups of cells (figure 8a,b) and an increase in the glycolytic pathway activity, which is in response to mitochondrial stressors, as observed in the statistical analysis of the energy phenotype (figure 8). Increased ECAR levels were reported as 2.10, 1.95, 2.01 and 1.81 mpH min µg⁻¹ with respect to 10, 25, 50 and 100 µM sulfatide treatment for non-transfected cells, respectively, and 4.34, 3.47, 3.47 and 2.41 mpH min µg⁻¹ for transfected cells, respectively.
3.6. Metformin in sulfatide metabolism

Non-transfected cells were exposed to 100 µM sulfatide, in which metformin treatment did not affect mitochondrial respiration (figure 9a). By contrast, as transfected cells did not respond to sulfatide exposure, a decrease in both basal respiration and maximal mitochondrial respiration, as well as mitochondrial respiratory capacity and percentage, was observed (figure 9c–f). In addition, simultaneous treatment with 100 µM sulforaphane and 500 µM metformin improved mitochondrial energy production in transfected cells (figure 9b). The above indicates that mitochondrial function was impaired at the expense of sulfatide accumulation. However, ATP was constantly produced in both groups of cells.

Phenotypic profiles of metformin in transfected and non-transfected cells were evaluated. Non-transfected cells showed to have an energy phenotype (figure 10a), while transfected cells that tended to be quiescent when exposed to 100 µM sulfatide and cells treated simultaneously with sulfatide and metformin recovered their initial energy profile.
Cells treated with metformin only are considerably more glycolytic (figure 10b). Transfected cells exposed to 100 µM sulfatide showed more metabolic alterations.

3.7. Mitochondrial reactive oxygen species

Statistically significant differences were observed between the two groups of cells (figure 11). Transfected cells exposed to 100 µM sulfatide produced superoxide anions. Treatment with metformin (500 µM) prevented the formation of superoxide anions in transfected cells (figure 12).

All these experiments were performed in triplicate and repeated in three independent assays for non-transfected cells. For transfected cells, due to the CRISPR-Cas9 gene editing that decreases the viability of these cells, only one assay was performed (see figure 13a,b).

4. Discussion

MLD is a lysosomal storage disease leading to sulfatide accumulation due to a deficiency of the lysosomal enzyme ARSA, causing clinical manifestations characterized by
progressive motor and cognitive deficits. The severity of the clinical course of MLD is determined by the residual ARSA activity, depending on the type of mutation [34]. Despite the efforts made to identify effective treatments for MLD, there are currently no effective therapeutic options available. Existing treatments, such as bone marrow or umbilical cord blood transplantation, cannot prevent disease progression [6]. Therefore, complementary therapies are required to improve the quality of life in patients with MLD. In this study, a genetic modification was performed by CRISPR-Cas9 genome editing using a lipid-based transfection procedure, in addition to a mutation in exon 2 of the ARSA gene in HSCs (ScienceCell Research Laboratories, USA), which is a method that has not been described in this cell type so far.

In addition, analysis of the theoretical three-dimensional structure model showed that the deletion of guanine nucleotide causes a premature termination codon within a protein in which the amino acid histidine at position 140 changes to isoleucine (H140I) [7]. The mutation found in this study is correlated with the heterozygous variant used as a positive control in the identification of infantile MLD according to the cohort study of McCreary et al. [35], in which a targeted approach using a panel of 257 genes was developed for a population of 60 children with suspected genetic neuroinflammation, which allowed the confirmation of molecular diagnosis in 20% of patients, and which outlined some unexpected genotype-phenotype associations and new pathogenic variants.

In our model of transfected Schwann cells with no ARSA activity, gene expression was analysed using RT-qPCR, showing a lower expression compared to the copy number expressed in non-transfected cells, which indicates that amino acid changes significantly affected the structure and function of ARSA protein. The above is in accordance with a study conducted by Guo et al. that described ARSA overexpression in mutant or transfected cells showing enhanced efficacy of ARSA enzyme against sulfatide metabolism [36–39].

The enzyme ARSA is responsible for the metabolism of the sphingolipid 3-o-sulfogalactosylceramide, known as sulfatide, which prevents its accumulation in lysosomes. This lipid plays an important role in both CNS and PNS in the myelination process. Therefore, a mutation in the gene encoding this enzyme would lead to an imbalance in this process [40]. Selected concentrations in this study that do not affect cell viability in Schwann cells were 10, 25, 50 and 100 µM based on the studies conducted by Blomqvist et al. [41], in which the developmental profile of lysosulfatide in the brain of ARSA-deficient mice was evaluated, in addition to the studies of Dai et al. [42] in which the accumulation of sulfatides and lysosulfatides in nerves and cerebrospinal fluid provides a marker of disease severity in the PNS only. C16:0 sulfatide (Matreya, Pleasant Gap, PA) in the range of 20–2000 ng mg⁻¹ of dry tissue and 400 ng mg⁻¹ of C12:0 sulfatide (ISTD, Avanti Polar Lipids) [42,43] were both used in this study.

Therefore, after selecting concentrations, the effects of different concentrations of sulfatides on transfected and non-transfected Schwann cells were evaluated. The viability of transfected Schwann cells was affected after exposure to 100 µM sulfatide. These data can be compared with the results obtained in other studies in which there was a correlation between the phenotype of ARSA-deficient mice observed and high levels of sulfatide [44]; Shaimardanova et al. [32], Rosenberg et al. [45] and Beerepoot et al. [46] confirmed that the presence of high concentrations of sulfatides in the CNS and PNS leads to demyelination due to the damage to myelin sheath covering most nerve fibres [34,45,46]. This damage is influenced by the accumulation of undigested lipids in the lysosome, which may invade other cell organelles, leading to enzyme deficiencies and triggering cell death [34].

Deficiencies of lysosomal enzymes lead to the development of lysosomal storage diseases, such as MLD, considering that these organelles are involved in a series of processes such as apoptosis and necrosis [47,48]. Necrosis was observed when...
Schwann cells were transfected after exposure to 100 µM sulfatide, while apoptosis was observed when cells were simultaneously exposed to 100 µM sulfatide and 500 µM metformin. The above is consistent with the fact that each type of cell in the human body has a different metabolism and therefore reacts according to the need for substrate. There is little information on MLD physiological processes [49] using sulfatide in pancreatic β-cells at 30 µM, which significantly reduces apoptosis, cell leakage and NO production [43].

Considering that the accumulation of metachromatic material in peripheral nerves in MLD has been previously reported, metachromatic material comprises Schwann cells and endoneurial macrophages that are filled with characteristic lysosomal sulfatide inclusions, also known as inclusion bodies [3,4]. The presence of sulfatide in these cells causes cell death and thus demyelination, leading to the onset of symptoms in patients with MLD [46].

This is the first study describing mitochondrial behaviour in live HSCs (non-transfected and transfected cells). Therefore, at the phenotypic level, transfected cells were quiescent when exposed to different concentrations of sulfatides, in contrast with non-transfected cells, as these showed an energetic profile found in the mitochondrial phenotype, in which transfected cells cannot use the metabolic

---

**Figure 12.** Decrease in mitochondrial superoxide production. Statistical significance was calculated by applying the Student’s test. \( p = 0.0414 \) (*\( p < 0.05 \)), \( p = 0.0001 \) (**\( p < 0.001 \)) for each of the concentrations compared between transfected and non-transfected cells.

**Figure 13.** (a) Phenotypic characteristics of non-transfected cells; (b) Phenotypic characteristics of transfected cells.
pathways of glycolysis and oxidative phosphorylation to meet their energy demands under stress conditions. This also correlates with the results of ROS generation and necrosis due to the same mitochondrial involvement [50].

When evaluating the global profiling of ROS in transfected Schwann cells, we found that these cells produced higher levels of superoxide at the mitochondrial level compared to non-transfected cells as transfected cells were exposed to different concentrations of sulfatides, which was statistically significant. However, the use of metformin decreased this production.

The positive charge on the phosphonium group in MitoSOX Red selectively directs this cell permeable HE derivative to mitochondria, where it accumulates as a function of the mitochondrial membrane potential and shows fluorescence upon oxidation and subsequent binding to mtDNA [51].

The generation of ROS and reactive nitrogen species (RNS) is an integral process in cellular functions. ROS and RNS include various chemicals with different reactivity, such as superoxide anion radicals (O2−), hydrogen peroxide (H2O2), peroxynitrite (ONOO−), hydroxyl radicals (OH·), nitrogen dioxide radicals (NO2·) and carbonate anion radicals (CO3−). ROS and RNS have been proposed as these play an important role in the regulatory mechanisms, biochemical signal transduction and defence response against microorganisms. However, excessive production and/or insufficient detoxification can lead to oxidative/nitrative damage via ROS and RNS, which induces modification of cellular components, including proteins, lipids and DNA [52].

Oxidative stress has been described as an imbalance in the generation and neutralization of ROS and RNS in living organisms, leading to the overproduction of steady-state ROS and RNS. Oxidative stress alters redox homeostasis in several diseases, such as atherosclerosis, cancer, neurodegenerative diseases and myocardial infarction, which may cause irreversible damage and exacerbate a disease state [53,54]. Similarly, defective autophagy leads to the accumulation of mitochondria within which ROS can be generated due to the exposure to cellular stress [55].

The treatment for MLD remains enigmatic. However, efforts should continue to focus on identifying alternative treatments to improve the quality of life of patients. Here, metformin was proposed as a treatment to ameliorate and reduce the effects caused by sulfatide accumulation at the mitochondrial level.

Metformin is a plant-based drug that has been widely used to treat diabetes since the 1950s [56]. This drug was chosen because, although it is a biguanide used as first-line treatment of type 2 diabetes, it has been widely proposed as an alternative treatment for other pathologies, such as Parkinson’s disease [57], Alzheimer’s disease [58], liver disease [13] and multiple sclerosis [59], among others, because it has multiple antioxidant, anti-inflammatory, anti-apoptotic and anti-cancer properties [60–62]. Metformin has been found to cross the blood–brain barrier and accumulate in the brain in vivo [63].

Metformin has been shown to act via both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms, and by inhibition of mitochondrial respiration, as well as by inhibition of mitochondrial glycerophosphate dehydrogenase and a mechanism involving the lysosome [13,64]. Labuzek et al. [63] demonstrated that metformin alters lysosomal pH, thereby activating lysosomal enzymes in microglia [63].

Treatment of transfected cells with metformin resulted in an increase in maximal mitochondrial respiration rates, as shown by normalization of the Seahorse XF Mito Cell Mito Stress test, compared to the decrease in this parameter evidenced in cells transfected and treated with sulfatide, indicating that this drug enhanced the response of mitochondrial metabolism. Similarly, a reduction in intracellular and mitochondrial ROS generation was observed.

5. Conclusion

The generation of transfected HSCs has been described for the first time, and the presence of sulfatides metabolically affects these cells at the mitochondrial level. Treatment with 500 µM metformin reduced ROS generation in cells and at the mitochondrial level. Metformin improved mitochondrial bioenergetic performance in cells harbouring ARSA mutations.

Ethics. This study was approved by the Ethics and Research Committee of the Colombian Cardiovascular Foundation (Acta 375 2015). However, it did not require the use of informed consent as our work was not based on cells directly obtained from patients but reference cells from the ScienCell repository.

Data accessibility. The datasets generated and/or analysed during this study are publicly available on the Open Science Framework (OSF) website [12].

Authors’ contributions. N.T.S.-Á.: data curation, formal analysis, investigation, methodology, writing—original draft and writing—review and editing; P.K.B.-N.: conceptualization, funding acquisition, project administration, resources, supervision, validation and writing—review and editing; J.T.-S.: data curation, formal analysis, investigation, methodology, supervision, validation, writing—original draft and writing—review and editing; N.C.S.-D.: conceptualization, funding acquisition, project administration, resources, supervision, validation and writing—review and editing.

All authors gave final approval for publication and agreed to be held accountable for the work performed therein.

Conflict of interest declaration. The authors declare that they have no conflict of interest.

Funding. This project was funded by the macroproject entitled ‘Sulfatide metabolism, glycolysis and mitochondrial function in metachromatic leukodystrophy’, which was part of the Call for Research Projects in Basic Sciences, 712-2015, of the Colombian Ministry of Science, Technology and Innovation. The principal researcher of this study was N.C.S.-D. The University of Santander funded publication fees of this article.

Acknowledgements. Special thanks to the Ministry of Science, Technology and Innovation for funding the macroproject, and to the Colombian Cardiovascular Foundation, the Laboratorio de Investigaciones Biotecnológicas (LIBB) and Mike Alexander Celis Rodríguez for his support and advice in flow cytometry analyses.

References

1. Doherty K, Frazier SB, Clark M, Childers A, Pruthi S, Wenger DÁ, Duis J. 2019 A closer look at ARSA activity in a patient with metachromatic leukodystrophy. Mol. Genet. Metab. Rep. 19, 100460. (doi:10.1016/j.ymgme.2019.100460)
2. Sanchez-Alvarez NT, Baarista-Niño PK, Trejos-Suárez J, Serrano-Diaz NC. 2021 Metformichromatim leukodystrophy: diagnosis and treatment challenges. *Biomaterie*, 2021 [http://doi.org/10.21931/RB/2021.06.03.32J]

3. Bonkowski J, Wilkes J, Barsdley T, Utkin VM, Stoddard G. 2018 Association of diagnosis of leukodystrophy with race and ethnicity among pediatric and adolescent patients. *JAMA Neurol*. 2018 [http://doi.org/10.1001/jamanetworkneurlogy.2018.5301]

4. Ozkan A, Özkan HA. 2016 Metachromatic leukodystrophy: biochemical characterization of two p.307Glu→Lys, p.318Trp→Cys arylsulfatase A mutations. *Intractable Rare Dis. Res.*, 5:280–283. [http://doi.org/10.5582/irdr.2016.01085]

5. Niida Y, Kuroda M, Mitani Y, Yokoi A, Ozaki M. 2012 Paternal uniparental isodisomy of chromosome 22 in a patient with metachromatic leukodystrophy. *J. Hum. Genet.*, 57:687–690. [http://doi.org/10.1038/jhg.2012.97]

6. The Human Gene Mutation Database. 2021 [http://www.hgmd.cf.ac.uk/ac/index.php?gene=ARSA](http://www.hgmd.cf.ac.uk/ac/index.php?gene=ARSA) allele. Accessed 12 July 2021. 

7. Golchin N, Hajjari M, Malamiri RA, Aminzadeh M, Mohammadi-asl J. 2017 Identification of a novel mutation in ARSA gene in three patients of an Iranian family with metachromatic leukodystrophy disorder. *Genet. Mol. Biol.*, 30:759–762. [http://doi.org/10.1590/1678-4685-GMB-2016-0110](http://doi.org/10.1590/1678-4685-GMB-2016-0110)

8. Gieselmann V. 2008 Metachromatic leukodystrophy: genetics, pathogenisis and therapeutic options. *Acta Paediatr.*, 97:15–21. [http://doi.org/10.1111/j.1651-2227.2008.00648.x](http://doi.org/10.1111/j.1651-2227.2008.00648.x)

9. Virgens MYE, Pol-Fachin L, Vettl H, Saraiva-Pereira ML. 2014 Effects of glycosylation and pH conditions in the dynamics of human arylsulfatase A. *J. Biomol. Struct. Dynamics*, 32:567–579. [http://doi.org/10.1080/07391102.2013.780982](http://doi.org/10.1080/07391102.2013.780982)

10. Bonkowski J, Wilkes J, Ying J, Wei WQ. 2020 Novel and known morbiditys of leukodystrophies identified using a phenome-wide association study. *Neuro. Clin. Pract.*, 10:406–414. [http://doi.org/10.1212/CNP.0000000000000783](http://doi.org/10.1212/CNP.0000000000000783)

11. Soukas AA, Hao H, Wu L. 2019 Metformin as anti-diabetic agent: is it for everyone? *Trends Endocrinol. Metab.* 30, 745–755. [http://doi.org/10.1016/j.tem.2019.07.015](http://doi.org/10.1016/j.tem.2019.07.015)

12. Chen J, Ou Y, Li Y, Hu S, Shao LW, Liu Y. 2017 Metformin extends C. elegans lifespan through nuclear factor-κB-dependent and known morbidities of leukodystrophies identified using a phenome-wide association study. *Neuro. Clin. Pract.*, 10:406–414. [http://doi.org/10.1212/CNP.0000000000000783](http://doi.org/10.1212/CNP.0000000000000783)

13. Renz G, Hardie DG, Pearson ER. 2017 The mechanisms of action of metformin. *Diabetologia*, 60, 1577–1585. [http://doi.org/10.1007/s00125-017-4342-z](http://doi.org/10.1007/s00125-017-4342-z)

14. Harrington M, Hareendran A, Skalicky A, Wilson H, Clark M, Milj J. 2019 Assessing the impact on caregivers caring for patients with rare pediatric lysosomal storage diseases: development of the caregiver impact questionnaire. *J. Patient Rep.*, 3, 89. [http://doi.org/10.1186/s13023-019-1000-2](http://doi.org/10.1186/s13023-019-1000-2)

15. SienceCell Research Laboratories. 2021 Human Schwann cells Ref. 1700 [http://www.siencecellonline.com/catalogsearch/result/?q=1700](http://www.siencecellonline.com/catalogsearch/result/?q=1700)

16. National Center for Biotechnology Information. 2021 BLAST: basic local alignment search tool. Accessed 13 December 2021. [https://blast.ncbi.nlm.nih.gov/blast.cgi](https://blast.ncbi.nlm.nih.gov/blast.cgi)

17. National Center for Biotechnology Information. 2019 Homo sapiens chromosome 22, GRCh38.p13 primary assembly. Accessed 13 December 2021. [http://www.ncbi.nlm.nih.gov/nuccore/NC_000022.11](http://www.ncbi.nlm.nih.gov/nuccore/NC_000022.11)

18. Liang L, Zhou L, Shao Y, Hu S, Liu Y. 2020 Metformin extends C. elegans lifespan through nuclear factor-KB-dependent and known morbidities of leukodystrophies identified using a phenome-wide association study. *Neuro. Clin. Pract.*, 10:406–414. [http://doi.org/10.1212/CNP.0000000000000783](http://doi.org/10.1212/CNP.0000000000000783)

19. Doerr J et al. 2019 Development and validation of a targeted next-generation sequencing panel for children with neuroinflammation. *JAMA Neurol.* 2, e1914274. [http://doi.org/10.1001/jamaneurol.2019.14274](http://doi.org/10.1001/jamaneurol.2019.14274)

20. Lee H, Jang S, Kang J, et al. 2021 Development and validation of a targeted next-generation sequencing panel for children with neuroinflammation. *JAMA Neurol.* 2, e1914274. [http://doi.org/10.1001/jamaneurol.2019.14274](http://doi.org/10.1001/jamaneurol.2019.14274)

21. AGENT/Pathogen Online Journal. 2021 *M. tuberculosis*. [http://doi.org/10.1016/j.jhmg.2012.09.002](http://doi.org/10.1016/j.jhmg.2012.09.002)

22. OukpnvfgIICad4YZV-LYRpmbcNQaAtIrEALw_wcB:G:s&s_kwcid=AL!3652!3!...
40. Takahashi T, Suzuki T. 2012 Role of sulfatide in normal and pathological cells and tissues. J. Lipid Res. 53, 1437–1450. (doi:10.1194/jlr.R206682)

41. Blomqvist M, Gieselmann V, Månsson JE. 2011 Accumulation of lyso sulfatide in brains of arylsulfatase A-deficient mice. Lipids Health Dis. 10, 28. (doi:10.1186/1476-511x-10-28)

42. Dalí C et al. 2015 Sulfatide levels correlate with severity of neuropathy in metachromatic leukodystrophy. Ann. Clin. Transl. Neurol. 2, 518–533. (doi:10.1002/acn3.193)

43. Roeske-Nielsen A, Dalgaard LT, Mansson JE, et al. 2012 Increasing sulfatide in the brain of arylsulfatase A-deficient mice. J. Neurosci. 32, 1130–1138. (doi:10.1523/JNEUROSCI.2287-07.2007)

44. Frati G et al. 2018 Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy. Cell Death Dis. 9, 698. (doi:10.1038/s41419-018-0373-0)

45. Xu Y, Shen J, Ran Z. 2020 Emerging views of apoptosis in immunity and autoimmune diseases. Autophagy 16, 3–17. (doi:10.1080/15548622.2019.1603547)

46. Bugiani M, Wolf NI. 2019 Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective. Neural. Plast. 2016, 240. (doi:10.1155/2016/1021/ja903922u)

47. Weiskopf B. 2010 Metformin increases phagocytosis and AMPK dependent manner in rat primary microglia. Proc. Natl Acad. Sci. USA 107, 186–190. (doi:10.1073/pnas.1002109107)

48. Elkawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udo H. 2015 Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc. Natl Acad. Sci. USA 112, 1809–1814. (doi:10.1073/pnas.1417636112)

49. Frati G et al. 2018 Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy. Cell Death Dis. 9, 698. (doi:10.1038/s41419-018-0373-0)